Background
Disease activity and treatment-related toxicity are the most important
contributors to poor prognosis in patients with ANCA-associated
vasculitis (AAV). Sometimes, it is difficult to distinguish them. We
present a case to highlight the challenges in the management of AAV and
the complications with immunosuppression.